|Bid||51.37 x 1100|
|Ask||51.58 x 1100|
|Day's Range||51.13 - 54.37|
|52 Week Range||49.12 - 109.53|
|Beta (5Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||143.85|
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Axsome Therapeutics (NASDAQ: AXSM) is approaching that important day in the life of a biotech when it shifts from unprofitable company to one that is marketing pharmaceuticals to the public. This specialist in drugs for the central nervous system is applying for two new drug applications with the Food and Drug Administration in 2021, and has two additional drugs just a year or two away from market. In this video clip from Motley Fool Live, recorded March 5, Corinne Cardina, bureau chief of healthcare and cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss Axsome.